Cerberus Therapeutics is focused on developing innovative immunological solutions through its unique platform technologies that leverage alpaca-derived single domain antibody fragments, known as VHHs. These technologies are designed to promote antigen-specific tolerance and address infectious diseases by re-engineering the immune system. Unlike conventional methods that suppress immune responses or target specific immunogenic regions of pathogens, Cerberus's approach encourages the immune system to utilize its own complex network, effectively allowing it to re-wire itself for better response and regulation.

The company has developed two distinct platforms for immune modulation: the Tolerance Induction Platform and the KappaLink Platform. These platforms aim to harness the power of VHHs to create targeted therapies that can modulate immune responses in a more sophisticated manner. By focusing on the body's inherent capabilities rather than merely inhibiting immune activity, Cerberus Therapeutics is pioneering a new direction in immunotherapy that could lead to more effective treatments for a variety of conditions.

United States

Cerberus Therapeutics utilizes nanobody-based platform to create novel therapeutics for modulating the immune system.

The COVID-19 pandemic highlights the need for safe and accessible therapies to modulate our immune responses. We have developed strategies that allows for precise turning on/off the immune system in response to debilitating diseases.

Our pilot programs focus on autoimmune disorders and infectious diseases, that are based on novel biological discoveries originating from decades of work by our three founders: Dr. Novalia Pishesha, Prof. Hidde Ploegh, and Prof. Harvey Lodish.

Cerberus Therapeutics

Company Details